The "Cancer / Tumor Profiling - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

The global market for Cancer / Tumor Profiling is estimated at US$10.3 Billion in 2023 and is projected to reach US$19.8 Billion by 2030, growing at a CAGR of 9.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the cancer/tumor profiling market is driven by several factors, including advancements in molecular profiling technologies, increased adoption of liquid biopsies, and the integration of AI and machine learning. The development of single-cell sequencing technologies offers granular insights into tumor heterogeneity, identifying subpopulations driving disease progression and therapy resistance. This level of detail supports the creation of more effective treatment strategies.

Moreover, AI and ML enhance the analysis of complex molecular data, improving the accuracy of profiling and enabling the prediction of patient outcomes. The expanding capabilities of these technologies, combined with their integration into clinical practice, promise more personalized and responsive cancer treatments, ultimately leading to better patient outcomes and continuous innovation in oncology.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Immunoassays Technology segment, which is expected to reach US$6.2 Billion by 2030 with a CAGR of a 9.3%. The Next Generation Sequencing Technology segment is also set to grow at 10.8% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $3.7 Billion in 2023, and China, forecasted to grow at an impressive 10.6% CAGR to reach $1.6 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players such as Caris Life Sciences, Genomic Health, Inc., Helomics Corporation, and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Key Attributes:

Key Topics Covered:

MARKET OVERVIEW

• Rise in Cancer Incidence Fosters Growth in Cancer / Tumor Profiling Market
• Select Cancer Statistics
• Total Number of New Cancer Cases by Type: 2022
• Total Number of Cancer Deaths by Type: 2022
• Cancer Incidence by Region: 2022
• Cancer Mortality by Region: 2022
• Tumor Profiling: At Zenith of Efforts to Expedite Transition from Histologic to Precision Cancer Treatment
• Global Market Analysis and Prospects
• Global Cancer/Tumor Profiling Market Looks Forward to Prolific Growth
• Genomic Profiling, NGS, Breast Cancer & Research: Thriving Segments of Cancer/Tumor Profiling Market
• NGS as Primary Technology Segment
• Breast Cancer & Pharmaceutical Segments to Exhibit Solid Gains
• Research Rules while Treatment Selection Posts Fastest Growth
• North America Clinches Commanding Stake on Global Cancer/Tumor Profiling Market
• Asia-Pacific Emerges as Lucrative Market
• Pulsating Trends Favoring Expansion of Cancer/Tumor Profiling Market
• Select Market Drivers
• Market Opportunities
• Competitive Landscape: Innovation and R&D Focus amid Fierce Competition
• Cancer / Tumor Profiling - Global Key Competitors Percentage Market Share in 2024 (E)
• Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• Recent Market Activity

MARKET TRENDS & DRIVERS

• Molecular Profiling Paves the Way for Personalized Cancer Treatment
• Introduction of Tumour Profiling Techniques Ensures Timely Treatment for Cancer Patients
• Application of Cancer/Tumor Profiling in Cancer Research Sees Significant Growth
• Transformative Advances in Tumor Profiling Technologies Revolutionize Cancer Treatment
• Liquid Biopsy: A Transformative Tool in Cancer Profiling, Diagnostics, and Monitoring
• Precision Oncology Holds Upside Potential with Advancements in Multi-Omics Tumor Profiling
• Leveraging AI and Machine Learning in Tumor Profiling Facilitates Cancer Care
• Precision Oncology Holds Upside Potential with Advancements in Multi-Omics Tumor Profiling
• Single-Cell Sequencing: Revolutionizing Cancer Research
• Tumor Profiling: A Catalyst for Precision Companion Diagnostics

FOCUS ON SELECT PLAYERS (Total 55 Featured)

• Caris Life Sciences
• Genomic Health, Inc.
• Helomics Corporation
• HTG Molecular Diagnostics, Inc.
• Illumina, Inc.
• Nanostring Technologies, Inc.
• NeoGenomics Laboratories, Inc.
• Oxford Gene Technology
• Qiagen NV
• Ribomed Biotechnologies, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/tkb2qu

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241004796903/en/